Hologic Dirección

Dirección controles de criterios 3/4

El CEO de Hologic's es Steve MacMillan , nombrado en Dec 2013, tiene una permanencia de 10.25 años. compensación anual total es $15.56M, compuesta por 7.6% salario y 92.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.49% de las acciones de la empresa, por valor de MX$1.44B. La antigüedad media del equipo directivo y de la junta directiva es de 3.1 años y 7 años, respectivamente.

Información clave

Steve MacMillan

Chief Executive Officer (CEO)

US$15.6m

Compensación total

Porcentaje del salario del CEO	7.6%
Permanencia del CEO	10.3yrs
Participación del CEO	0.5%
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve MacMillan en comparación con los beneficios de Hologic?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 30 2023	n/a	n/a	US$515m
Sep 30 2023	US$16m	US$1m	US$456m
Jul 01 2023	n/a	n/a	US$484m
Apr 01 2023	n/a	n/a	US$753m
Dec 31 2022	n/a	n/a	US$990m
Sep 24 2022	US$14m	US$1m	US$1b
Jun 25 2022	n/a	n/a	US$2b
Mar 26 2022	n/a	n/a	US$2b
Dec 25 2021	n/a	n/a	US$2b
Sep 25 2021	US$15m	US$1m	US$2b
Jun 26 2021	n/a	n/a	US$2b
Mar 27 2021	n/a	n/a	US$2b
Dec 26 2020	n/a	n/a	US$1b
Sep 26 2020	US$14m	US$1m	US$1b
Jun 27 2020	n/a	n/a	US$497m
Mar 28 2020	n/a	n/a	US$453m
Dec 28 2019	n/a	n/a	US$84m
Sep 28 2019	US$12m	US$1m	-US$204m
Jun 29 2019	n/a	n/a	-US$30m
Mar 30 2019	n/a	n/a	-US$11m
Dec 29 2018	n/a	n/a	-US$419m
Sep 29 2018	US$42m	US$1m	-US$111m
Jun 30 2018	n/a	n/a	-US$79m
Mar 31 2018	n/a	n/a	-US$132m
Dec 30 2017	n/a	n/a	US$1b
Sep 30 2017	US$11m	US$1m	US$756m

Compensación vs. Mercado: La compensación total de Steve($USD15.56M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD6.07M).

Compensación vs. Ingresos: La compensación de Steve ha sido consistente con los resultados de la empresa en el último año.

CEO

Steve MacMillan (59 yo)

10.3yrs

Permanencia

US$15,555,032

Compensación

Mr. Stephen P. MacMillan, also known as Steve, serves as Chairman of the Board at Illumina, Inc. from June 02, 2023. He has been the Chairman of the Board at Hologic Inc. since June 17, 2015 and its Chief...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen MacMillan	Chairman	10.3yrs	US$15.56m	0.49% $ 1.4b
Karleen Oberton	Chief Financial Officer	5.6yrs	US$3.93m	0.044% $ 130.2m
Essex Mitchell	Chief Operating Officer	less than a year	US$2.17m	0.00018% $ 529.6k
John Griffin	General Counsel	9.1yrs	US$3.34m	0.045% $ 133.8m
Jan Verstreken	Group President of International	no data	US$3.52m	0.031% $ 91.1m
Paul Malenchini	Chief Information Officer	2.7yrs	sin datos	sin datos
Ryan Simon	Vice President of Investor Relations	no data	sin datos	sin datos
Peter Dunne	Senior Vice President of Human Resources	less than a year	sin datos	0.0040% $ 11.8m
Monica Berthelot	VP & Chief of Staff	10.2yrs	sin datos	sin datos
Erik Anderson	Division President of Breast & Skeletal Health Solutions	3.6yrs	sin datos	0.0070% $ 20.7m
Jennifer Schneiders	President of Diagnostics Solutions	less than a year	sin datos	0.0027% $ 7.9m
Scott Christensen	Senior Vice President of Global Supply Chain	less than a year	sin datos	sin datos

3.1yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HOLX * se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen MacMillan	Chairman	10.3yrs	US$15.56m	0.49% $ 1.4b
Scott Garrett	Independent Director	10.8yrs	US$339.96k	0.017% $ 51.3m
Sally Crawford	Lead Independent Director	16.4yrs	US$374.96k	0.055% $ 162.8m
Stacey Stewart	Independent Director	1.2yrs	US$338.44k	0.00011% $ 323.6k
Ludwig Hantson	Independent Director	5.3yrs	US$319.96k	0.0019% $ 5.5m
Charles Dockendorff	Independent Director	6.8yrs	US$344.96k	0.0066% $ 19.3m
Christiana Stamoulis	Independent Director	12.3yrs	US$319.96k	0.018% $ 53.2m
Namal Nawana	Independent Director	6.2yrs	US$319.96k	0.0071% $ 21.0m
Amy Wendell	Independent Director	7.3yrs	US$319.96k	0.0075% $ 22.2m
Nanaz Mohtashami	Independent Director	less than a year	US$128.96k	0% $ 0

7.0yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de HOLX * se considera experimentada (7 años de antigüedad promedio).

Hologic Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Independent Director recently sold Mex$12m worth of stock

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Insider recently sold Mex$9.3m worth of stock

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Recent updates

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director recently sold Mex$12m worth of stock

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Insider recently sold Mex$9.3m worth of stock

Full year 2023 earnings released: EPS: US$1.85 (vs US$5.18 in FY 2022)

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

New minor risk - Earnings quality

Insufficient new directors

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023

Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Hologic, Inc. Announces Approval of NovaSure V5 Global Endometrial Ablation Device in Canada and Europe

First quarter 2023 earnings released: EPS: US$0.76 (vs US$1.97 in 1Q 2022)

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Hologic, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Hologic, Inc., Annual General Meeting, Mar 09, 2023

Hologic, Inc. Revises Revenue Results for the First Quarter of Fiscal 2023

Hologic, Inc. to Report Q1, 2023 Results on Feb 01, 2023

Insider recently sold Mex$2.5m worth of stock

Hologic, Inc. Appoints Stacey D. Stewart to the Board of Directors, Effective January 2, 2023

Hologic, Inc. and Biotheranostics, Inc. Announce New Data Present At SABCS 2022

Chairman recently sold Mex$49m worth of stock

Insufficient new directors

Full year 2022 earnings released: EPS: US$5.18 (vs US$7.28 in FY 2021)

Hologic, Inc. Provides Earnings Guidance for the First Quarter Ending December 31, 2022 and Year Ending September 30, 2023

Insufficient new directors

Hologic, Inc. to Report Q4, 2022 Results on Oct 31, 2022

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,000 million worth of its shares.

Insufficient new directors

Hologic, Inc. Announces Separation of Sean S. Daugherty as President, Effective September 30, 2022

U.S. Court of Appeals for the Federal Circuit Affirms Ruling on Minerva Surgical, Inc. and Hologic, Inc. Case

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter Ending September 24, 2022

Hologic, Inc. Announces Two New Respiratory Assays for the Detection of COVID-19, Flu A, Flu B and RSV

Hologic, Inc. to Report Q3, 2022 Results on Jul 27, 2022

Insufficient new directors

Hologic Announces FDA Approval of Aptima CMV Quant Assay for Human Cytomegalovirus

Hologic, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Hologic, Inc. to Report Q2, 2022 Results on Apr 27, 2022

Insufficient new directors

Hologic, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2022

Hologic, Inc. Provides Preliminary Revenue Guidance for First Fiscal Quarter Ended December 25, 2021

Hologic Adds Aptima SARS-CoV-2 Assay to Its Global Access Initiative in Resource-Limited Countries

Hologic, Inc. Launches Panther Trax for High Volume Molecular Testing

Hologic, Inc. and Biotheranostics, Inc. Presents Breast Cancer Index™ Data at SABCS 2021 Showing Net Benefit Predictive Value for Endocrine Therapy Continuation

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Bolder Surgical, LLC from Providence Ventures, LLC.

Insider recently sold Mex$4.1m worth of stock

Hologic, Inc. to Showcase its Extensive Portfolio of Breast and Skeletal Health Products At RSNA 2021

Full year 2021 earnings released: EPS US$7.28 (vs US$4.25 in FY 2020)

Third quarter 2021 earnings released: EPS US$1.05 (vs US$0.53 in 3Q 2020)

Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

Hologic, Inc.(NasdaqGS:HOLX) dropped from Russell 1000 Growth Index

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Mobidiag Oy from Autobio Diagnostics Co., Ltd. (SHSE:603658) and others for an enterprise value of approximately $810 million

Hologic, Inc. Announces American College of Obstetricians and Gynecologists' Updated Guidance Supports Use of Laparoscopic Radiofrequency Ablation for the Treatment of Uterine Fibroids

Insider recently sold Mex$5.2m worth of stock

Second quarter 2021 earnings released: EPS US$2.40 (vs US$0.37 in 2Q 2020)

Hologic, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2021

Hologic, Inc. (NasdaqGS:HOLX) acquired Diagenode s.a. for approximately $160 million.

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of BioTheranostics, Inc.